Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

Overview of attention for article published in Frontiers in immunology, April 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 7 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 20 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 35,757 followers.

Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution https://t.co/coCYSNMVzt

05 May 2023

Reply Repost Favourite

RT @jgarciadonas: Our paper on COVID is out! https://t.co/ryy5nBguSk

25 Apr 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine…

19 Apr 2023

Reply Repost Favourite

New Research: Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution: Background Managing the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency.… https://t.co/A3do74k

18 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.